News
Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...
Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...
A recent study presented at the 2025 International Society for Heart and Lung Transplantation (ISHLT) annual meeting suggests ...
FAT jabs can treat a liver disease affecting one in five people, a trial found. Semaglutide cut inflammation in two thirds of ...
The global race for weight loss solutions has firmly arrived in India—bringing with it hope, hype, and a host of unanswered ...
Protein is a cornerstone nutrient for maintaining overall health, but its significance becomes especially prominent for those ...
Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results